+

CY1123577T1 - Ενωσεις 7-φαινυλοαιθυλαμινο-4η-πυριμιδο[4,5-d][1,3]οξαζιν-2-ονης ως αναστολεις μεταλλαγμενου idh1 και idh2 - Google Patents

Ενωσεις 7-φαινυλοαιθυλαμινο-4η-πυριμιδο[4,5-d][1,3]οξαζιν-2-ονης ως αναστολεις μεταλλαγμενου idh1 και idh2

Info

Publication number
CY1123577T1
CY1123577T1 CY20201101122T CY201101122T CY1123577T1 CY 1123577 T1 CY1123577 T1 CY 1123577T1 CY 20201101122 T CY20201101122 T CY 20201101122T CY 201101122 T CY201101122 T CY 201101122T CY 1123577 T1 CY1123577 T1 CY 1123577T1
Authority
CY
Cyprus
Prior art keywords
idh2
pyrimide
phenylethylamino
oxazine
inhibitors
Prior art date
Application number
CY20201101122T
Other languages
English (en)
Inventor
Renato Alejandro BAUER
Serge Louis Boulet
Timothy Paul Burkholder
Raymond Gilmour
Patric James Hahn
Zoran Rankovic
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1123577T1 publication Critical patent/CY1123577T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Μία ένωση, όπως ορίζεται στο παρόν, ή φαρμακευτική σύνθεση που περιέχει την ένωση για χρήση στη θεραπεία καρκίνου μεταλλαγμένου IDH1 ή IDH2 και που έχει τη δομή: (Ι).
CY20201101122T 2016-12-16 2020-11-25 Ενωσεις 7-φαινυλοαιθυλαμινο-4η-πυριμιδο[4,5-d][1,3]οξαζιν-2-ονης ως αναστολεις μεταλλαγμενου idh1 και idh2 CY1123577T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662435283P 2016-12-16 2016-12-16
PCT/US2017/065246 WO2018111707A1 (en) 2016-12-16 2017-12-08 7-phenylethylamino-4h-pyrimido[4,5-d][1,3]oxazin-2-one compounds as mutant idh1 and idh2 inhibitors

Publications (1)

Publication Number Publication Date
CY1123577T1 true CY1123577T1 (el) 2022-03-24

Family

ID=60888651

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201101122T CY1123577T1 (el) 2016-12-16 2020-11-25 Ενωσεις 7-φαινυλοαιθυλαμινο-4η-πυριμιδο[4,5-d][1,3]οξαζιν-2-ονης ως αναστολεις μεταλλαγμενου idh1 και idh2

Country Status (37)

Country Link
US (3) US11001596B2 (el)
EP (2) EP3555105B1 (el)
JP (1) JP6793836B2 (el)
KR (1) KR102276022B1 (el)
CN (2) CN110072867B (el)
AU (2) AU2017378060B2 (el)
CA (1) CA3045303C (el)
CL (1) CL2019001551A1 (el)
CO (1) CO2019005287A2 (el)
CR (1) CR20190252A (el)
CY (1) CY1123577T1 (el)
DK (1) DK3555105T3 (el)
DO (1) DOP2019000163A (el)
EA (1) EA036112B1 (el)
EC (1) ECSP19042682A (el)
ES (2) ES2941631T3 (el)
HR (1) HRP20201882T1 (el)
HU (1) HUE052067T2 (el)
IL (1) IL267236B (el)
JO (1) JOP20190142B1 (el)
LT (1) LT3555105T (el)
MA (2) MA47399B1 (el)
MD (1) MD3555105T2 (el)
MX (1) MX385562B (el)
MY (1) MY197313A (el)
NZ (1) NZ754115A (el)
PE (1) PE20190977A1 (el)
PH (1) PH12019501328B1 (el)
PL (1) PL3555105T3 (el)
PT (1) PT3555105T (el)
RS (1) RS61108B1 (el)
SA (1) SA519401897B1 (el)
SI (1) SI3555105T1 (el)
TN (1) TN2019000158A1 (el)
UA (1) UA123640C2 (el)
WO (1) WO2018111707A1 (el)
ZA (1) ZA201903125B (el)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016044787A1 (en) 2014-09-19 2016-03-24 Forma Therapeutics, Inc. Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
AU2015317322B2 (en) 2014-09-19 2020-09-17 Forma Therapeutics, Inc. Phenyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
PE20171056A1 (es) 2014-09-19 2017-07-21 Forma Therapeutics Inc Derivados de piridin-2(1h)-on quinolinona como inhibidores de isocitrato deshidrogenasa
EP3194383B1 (en) 2014-09-19 2019-11-06 Forma Therapeutics, Inc. Quinolinone pyrimidines compositions as mutant-isocitrate dehydrogenase inhibitors
WO2016171756A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Quinolinone five-membered heterocyclic compounds as mutant-isocitrate dehydrogenase inhibitors
WO2016171755A1 (en) 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
ES2751902T3 (es) 2016-10-24 2020-04-02 Astrazeneca Ab Derivado de 6,7,8,9-tetrahidro-3H-pirazolo[4,3-f]isoquinolina útil en el tratamiento del cáncer
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
EP3555097B1 (en) 2016-12-16 2022-06-15 Janssen Pharmaceutica NV Imidazo[4,5-d]pyrrolo[2,3-b]pyridine compounds as inhibitors of janus kinases
PT3555105T (pt) * 2016-12-16 2020-12-21 Lilly Co Eli Compostos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]oxazin-2-ona como inibidores de idh1 e idh2 mutantes
UA125043C2 (uk) 2017-01-30 2021-12-29 Астразенека Аб Модулятори рецептора естрогену
US10532047B2 (en) 2018-05-16 2020-01-14 Forma Therapeutics, Inc. Solid forms of ((S)-5-((1-(6-chloro-2-oxo-1,2-dihydroquinolin-3-yl)ethyl)amino)-1-methyl-6-oxo-1,6-dihydropyridine-2-carbonitrile
US20210196701A1 (en) 2018-05-16 2021-07-01 Forma Therapeutics, Inc. Inhibiting mutant idh-1
US11311527B2 (en) 2018-05-16 2022-04-26 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mIDH-1)
US11013733B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Inhibiting mutant isocitrate dehydrogenase 1 (mlDH-1)
US11013734B2 (en) 2018-05-16 2021-05-25 Forma Therapeutics, Inc. Treating patients harboring an isocitrate dehydrogenase-1 (IDH-1) mutation
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
WO2021089395A1 (en) * 2019-11-08 2021-05-14 Nerviano Medical Sciences S.R.L. Gem-disubstituted heterocyclic compounds and their use as idh inhibitors
IL296092A (en) * 2020-03-23 2022-11-01 Lilly Co Eli Combination therapy with a mutant idh inhibitor
EP4125916B1 (en) * 2020-03-23 2024-04-17 Eli Lilly And Company Method for treating idh1 inhibitor-resistant subjects
US20230135992A1 (en) * 2020-03-23 2023-05-04 Eli Lilly And Company Combination therapy with a mutant idh inhibitor and a bcl-2 inhibitor
CN115768775B (zh) * 2020-06-28 2024-10-25 微境生物医药科技(上海)有限公司 Idh突变体抑制剂及其用途
US20230255973A1 (en) * 2020-07-20 2023-08-17 Eli Lilly And Company Combination therapy with a mutant idh1 inhibitor, a deoxyadenosine analog, and a platinum agent
CN113588768B (zh) * 2021-05-18 2022-07-05 国家卫生健康委科学技术研究所 一种以分子图像方式定量组织内内源性代谢物的质谱方法
EP4337217A1 (en) 2021-06-09 2024-03-20 Eli Lilly and Company Method for treating idh inhibitor-resistant subjects
CA3217608A1 (en) * 2021-06-15 2022-12-22 Yuli Xie Idh mutant inhibitor and use thereof
US11746115B2 (en) 2021-08-13 2023-09-05 Eli Lilly And Company Solid forms of 7-[[(1S)-1-[4-[(1S)-2-cyclopropyl-1-(4-prop-2-enoylpiperazin-1-yl)ethyl]phenyl]ethyl]amino]-1-ethyl-4H-pyrimido[4,5-d][1,3]oxazin-2-one
WO2023141087A1 (en) 2022-01-19 2023-07-27 Eli Lilly And Company Combination therapy with a mutant idh inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140069235A (ko) 2011-09-27 2014-06-09 노파르티스 아게 돌연변이체 idh의 억제제로서의 3-피리미딘-4-일-옥사졸리딘-2-온
EP2970242B1 (en) * 2013-03-14 2017-09-06 Novartis AG 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
WO2014147586A1 (en) * 2013-03-22 2014-09-25 Novartis Ag 1-(2-(ethylamino)pyrimidin-4-yl)pyrrolidin-2-ones as inhibitors of mutant idh
WO2016171755A1 (en) * 2015-04-21 2016-10-27 Forma Therapeutics, Inc. Fused-bicyclic aryl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
US10471507B2 (en) * 2015-04-24 2019-11-12 Halliburton Energy Services, Inc. Methods of fabricating ceramic or intermetallic parts
US10253041B2 (en) * 2015-07-27 2019-04-09 Eli Lilly And Company 7-phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds and their use as mutant IDH1 inhibitors
EP3464281B1 (en) * 2016-06-06 2020-07-08 Eli Lilly and Company Mutant idh1 inhibitors
PT3555105T (pt) * 2016-12-16 2020-12-21 Lilly Co Eli Compostos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]oxazin-2-ona como inibidores de idh1 e idh2 mutantes

Also Published As

Publication number Publication date
ZA201903125B (en) 2024-08-28
CN115109075A (zh) 2022-09-27
MA47399B1 (fr) 2021-02-26
MX2019006830A (es) 2019-08-22
US11649247B2 (en) 2023-05-16
ECSP19042682A (es) 2019-06-30
CR20190252A (es) 2019-08-26
MY197313A (en) 2023-06-13
HUE052067T2 (hu) 2021-04-28
SI3555105T1 (sl) 2020-12-31
CA3045303C (en) 2022-05-17
AU2020260493B2 (en) 2021-09-09
IL267236B (en) 2020-08-31
JOP20190142B1 (ar) 2023-03-28
DOP2019000163A (es) 2019-07-15
DK3555105T3 (da) 2020-11-09
EP3763717A1 (en) 2021-01-13
US20200079791A1 (en) 2020-03-12
MA47399A (fr) 2019-10-23
KR20190077539A (ko) 2019-07-03
ES2835281T3 (es) 2021-06-22
CN110072867B (zh) 2022-07-08
JP2020502157A (ja) 2020-01-23
ES2941631T3 (es) 2023-05-24
AU2017378060A1 (en) 2019-05-30
BR112019009648A2 (pt) 2019-09-10
CN115109075B (zh) 2024-09-20
IL267236A (en) 2019-08-29
WO2018111707A1 (en) 2018-06-21
US11001596B2 (en) 2021-05-11
US20210206780A1 (en) 2021-07-08
EP3555105A1 (en) 2019-10-23
LT3555105T (lt) 2021-01-11
RS61108B1 (sr) 2020-12-31
EA201991161A1 (ru) 2019-11-29
AU2020260493A1 (en) 2020-11-26
US11629156B2 (en) 2023-04-18
CN110072867A (zh) 2019-07-30
KR102276022B1 (ko) 2021-07-13
PH12019501328B1 (en) 2023-05-12
SA519401897B1 (ar) 2022-07-28
MA53881A (fr) 2022-04-27
EP3763717B1 (en) 2023-03-08
CL2019001551A1 (es) 2019-10-25
TN2019000158A1 (en) 2020-10-05
UA123640C2 (uk) 2021-05-05
EA036112B1 (ru) 2020-09-29
PE20190977A1 (es) 2019-07-09
JOP20190142A1 (ar) 2019-06-13
MX385562B (es) 2025-03-18
MD3555105T2 (ro) 2021-01-31
CO2019005287A2 (es) 2019-05-31
PH12019501328A1 (en) 2020-02-24
PT3555105T (pt) 2020-12-21
NZ754115A (en) 2021-07-30
JP6793836B2 (ja) 2020-12-02
US20210230185A1 (en) 2021-07-29
EP3555105B1 (en) 2020-10-28
AU2017378060B2 (en) 2020-09-03
CA3045303A1 (en) 2018-06-21
PL3555105T3 (pl) 2021-05-17
HRP20201882T1 (hr) 2021-01-22

Similar Documents

Publication Publication Date Title
CY1123577T1 (el) Ενωσεις 7-φαινυλοαιθυλαμινο-4η-πυριμιδο[4,5-d][1,3]οξαζιν-2-ονης ως αναστολεις μεταλλαγμενου idh1 και idh2
CY1123666T1 (el) Φαρμακευτικες ενωσεις
CY1124798T1 (el) Υποκατεστημενα παραγωγα καρβονουκλεοζιδιων χρησιμα ως παραγοντες κατα των καρκινων
CY1125193T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν μελοξικαμη
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
CY1125145T1 (el) Αναστολεις cd73
CO2019008487A2 (es) Compuesto de quinazolina
BR112019024525A2 (pt) composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c
CY1120619T1 (el) Χημικες οντοτητες
EA201892229A1 (ru) Замещенные аминопуриновые соединения, содержащие их композиции и способы лечения с их применением
CL2016001231A1 (es) Compuestos de inhibidor de autotaxina
CY1123592T1 (el) Αναστολεας κινασης aurora a
TW201613887A (en) Antiproliferative compounds and methods of use thereof
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
CY1121554T1 (el) Παραγωγο πυρανοχρωμενυλ-φαινολης, και φαρμακευτικη συνθεση για αγωγη μεταβολικου συνδρομου ή φλεγμονωδους παθησης
HUE063145T2 (hu) Deuterált vegyületek rákos megbetegedések kezelésében történõ alkalmazásra
BR112015026021A2 (pt) terapia de combinação compreendendo um inibidor de tor quinase e n-(3-(5-flúor-2-(4-(2-met-oxietoxi)fenilamino)pirimidin-4-ilamino)fenil)acrilamida para o tratamento de câncer
MX390435B (es) Inhibidor selectivo de receptor de factor de crecimiento epidermico mutante de insercion de exon 20.
CY1120573T1 (el) Παραγωγα πυριδαζινης για χρηση στην προληψη ή θεραπεια αταξικης διαταραχης
CY1122971T1 (el) Ενωσεις διυδροπυριμιδιν-2-ονης και ιaτρικη χρηση αυτων
MX390051B (es) Antagonistas de ep4.
MX389899B (es) Compuesto macrocíclico y sus usos.
EP3868385A4 (en) GASTRIC CANCER TREATMENT COMPOSITION INCLUDING A SYT11 INHIBITOR AS AN ACTIVE INGREDIENT
CY1122656T1 (el) Λιπαντικο συμπλοκο για το στομα
CY1124415T1 (el) Μειωση της απορροφησης οξαλικων ενωσεων σε ανθρωπους
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载